Announced details
Our company is participating in both research projects as a research and development collaborator and will work with the institutions leading the research and other relevant institutions. We will cooperate on regulatory affairs and clinical development, protocol development, provision of the drug, and sharing of safety information.
AMED is a national research and development agency. Osaka Medical and Pharmaceutical University and Okayama University are listed as the institutions leading the research projects. Other information, including location, representative, capital, and year of establishment, is not disclosed.
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Japan Agency for Medical Research and Development (AMED), Clinical Research and Clinical Trial Promotion Research Program
| Item | Details |
|---|---|
| Names of Products / Services Covered | Boron neutron capture therapy (BNCT), Boron neutron immunotherapy (B-NIT), Steboronin® intravenous infusion bag 9000 mg/300 mL |
| Counterparty | Japan Agency for Medical Research and Development (AMED), Osaka Medical and Pharmaceutical University, Okayama University |
| Counterparty overview | AMED is a national research and development agency. Osaka Medical and Pharmaceutical University and Okayama University are listed as the institutions leading the research projects. Other information, including location, representative, capital, and year of establishment, is not disclosed. |
| Relationship with the Company | Our company is participating in both research projects as a research and development collaborator and will work with the institutions leading the research and other relevant institutions. We will cooperate on regulatory affairs and clinical development, protocol development, provision of the drug, and sharing of safety information. |
| Applicable area | Malignant spinal glioma, Unresectable, BRAF-negative, advanced melanoma, Central nervous system diseases, Deep-seated, treatment-resistant cancers, Rare cancers |
| Source | Japan Agency for Medical Research and Development (AMED), Clinical Research and Clinical Trial Promotion Research Program |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To explore the potential of BNCT as a new treatment option in disease areas where existing treatment options are limited, and to establish a foundation for conducting future investigator-initiated clinical trials.